Abstract
Surgery is the only therapy able to cure patients with digestive neuroendocrine tumor. However, due to the presence of diffuse metastases, radical surgery is often not feasible. In these cases, medical treatment plays a critical role, because of its ability to control symptoms in functioning tumors and to inhibit tumor growth. Different therapeutic approaches, such as chemotherapy, hepatic artery chemoembolization and targeted radio-nuclide therapy can be used alone or combined to the biologic treatment with somatostatin analogues and interferon. However, an accurate staging by imaging procedures plus a histological, immunohistochemical and biomolecular examination must be performed before planning an optimal medical treatment.
MeSH terms
-
Algorithms
-
Antineoplastic Agents, Hormonal / therapeutic use*
-
Carcinoid Tumor / drug therapy
-
Carcinoid Tumor / pathology
-
Carcinoid Tumor / radiotherapy
-
Cell Differentiation
-
Combined Modality Therapy
-
Digestive System Neoplasms / drug therapy*
-
Digestive System Neoplasms / pathology
-
Digestive System Neoplasms / radiotherapy
-
Embolization, Therapeutic
-
Humans
-
Indium Radioisotopes / therapeutic use
-
Neoplasm Proteins / drug effects
-
Neoplasm Staging
-
Neuroendocrine Tumors / drug therapy*
-
Neuroendocrine Tumors / pathology
-
Neuroendocrine Tumors / radiotherapy
-
Octreotide / analogs & derivatives*
-
Octreotide / therapeutic use
-
Pentetic Acid / analogs & derivatives*
-
Pentetic Acid / therapeutic use
-
Peptides, Cyclic / therapeutic use
-
Receptors, Somatostatin / drug effects
-
Retrospective Studies
-
Somatostatin / analogs & derivatives
-
Somatostatin / therapeutic use
-
Treatment Outcome
Substances
-
Antineoplastic Agents, Hormonal
-
Indium Radioisotopes
-
Neoplasm Proteins
-
Peptides, Cyclic
-
Receptors, Somatostatin
-
lanreotide
-
SDZ 215-811
-
Somatostatin
-
Pentetic Acid
-
Octreotide